IMPACT OF BODY COMPOSITION ON PHARMACOKINETICS OF DOXORUBICIN

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。格拉泽儿科研究网络是一个创新的合作伙伴关系，将科学中心联系起来，以加速严重和危及生命的儿科疾病的进展。格拉泽儿科研究网络的一个主要目标是确保，随着新疗法的开发，医生更快地了解他们的儿科应用。参与研究的中心有麻省理工学院、哈佛大学、斯坦福大学、加州大学洛杉矶分校、加州大学旧金山分校。阿霉素的药代动力学行为与体重指数和身体成分有关，尚未得到很好的表征。该方案在格拉泽儿科研究网络内进行，旨在获得21岁或以下儿童单次静脉给药后身体组成对多柔比星药代动力学行为影响的详细信息。无疗效成分。大约45名儿童将被招募。从这项研究中获得的信息可能是非常重要的，在制定多柔比星在肥胖患者人群的剂量策略。假设身体成分可能影响阿霉素的药代动力学参数。特别是，根据体重指数标准肥胖或通过DEXA扫描测量的体脂百分比高的患者可能具有降低的阿霉素清除率。具体目标评价儿童肥胖与阿霉素药代动力学之间的关系。次要目的：根据体重指数（BMI）确定肥胖/非肥胖儿童的身体组成。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Glaser Pediatric Research Network, an innovative and collaborative partnership, linking scientific centers to accelerate progress on serious and life-threatening pediatric illnesses. A primary objective of the Glaser Pediatric Research Network is to ensure that, as new therapies are developed, physicians learn more quickly about their pediatric applications. The participating centers are BCM, Harvard, Stanford, UCLA, UCSF.The pharmacokinetic behavior of doxorubicin as it relates to body mass index and body composition has not been well characterized. This protocol, being performed within the Glaser Pediatric Research Network, is designed to obtain detailed information on the impact of body composition on the pharmacokinetic behavior of doxorubicin after a single intravenous dose in children 21 years of age or younger. There is no efficacy component. Approximately 45 children will be enrolled. The information gained from this study could be very important in developing dosing strategies for doxorubicin in the obese patient population. HYPOTHESIS Body composition may affect the pharmacokinetic parameters of doxorubicin. In particular, patients who are obese by body mass index criteria or who have a high percentage of body fat as measured by DEXA scanning may have decreased doxorubicin clearance. SPECIFIC AIMSPrimary: To evaluate the relationship between obesity and doxorubicin pharmacokinetics in children.Secondary: To determine body composition in children who are categorized as obese/non-obese based on body mass index (BMI).